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Poster Session II 141enrolled in the SIR/CSP study and 17 in the SIR/TAC study. All
patients had high-risk hematologic malignancies. Twenty four
patients had HLA-matched donors and 22 received growth fac-
tor-mobilized peripheral blood cells. The preparative regimens
were total body irradiation/cyclophosphamide (CY) (17) or busul-
fan/CY (9). Grade II-IV acute GVHD was observed in 20 (91%)
of 22 patients who could be evaluated, 7 of 7 in the CSP Group
and 13 of 15 in the TAC Group, and all required glucocorticoid
therapy. Four patients could not be evaluated due to early death
(1) or glucocorticoid treatment for pulmonary complications (3).
The median onset of GVHD was day 6 and 7 in the CSP and
TAC Groups, respectively. GVHD was confirmed by biopsy in
16 patients. Mean SIR levels through day 30 were 11.7 and
8.8 ng/mL in the CSP and TAC Groups, respectively, with only
2% and 11% of levels below the target range. At the onset of
GVHD, 5 patients (26%) had SIR levels below the target range.
The mean CSP and TAC levels through day 30 were 324 ng/mL
and 9.6 ng/mL, respectively, with 2 patients in the TACGroup hav-
ing levels below the target range at the onset of GVHD. Twelve of
26 patients (46%) discontinued administration of SIR early due to
cytopenia (5), hemolytic-uremic syndrome or renal failure (4), ab-
normal liver function tests (1), hyperlipidemia (1) or elevated siroli-
mus level (1). Three patients in the TAC Group required
hemodialysis. Nineteen of 20 patients developed GVHD before
SIR was discontinued. Sixteen patients (62%) were alive at one
year after HCT. Accrual in both studies was terminated when it be-
came apparent that there was no detectable improvement inGVHD
incidence.387
EFFECT OF ACUTE AND CHRONIC GVHD ON OVERALL SURVIVAL IN 122
UNRELATED TRANSPLANTS FOR MALIGNANT DISEASES PERFORMED
OVER TEN YEARS IN A SINGLE CENTER IN BRAZIL
Funke, V.A.M., Nunes, E.C., Medeiros, L., Setubal, D.C., Ruiz, J.,
Oliveira, M.M., Bittencourt, M.A., Bonfim, C., Neto, J.Z.,
Medeiros, C.R., Pasquini, R. Hospital de Clınicas - Federal University
of Parana, Curitiba, Parana, Brazil.
Acute and chronic graft-versus-host disease are well known
causes of transplant related mortality among unrelated transplants.
Objective: evaluate the impact of acute and chronicGVHDat the
overall survival among 122 unrelated transplants performed from
07/95 to 06/05 at the BMT center of HC-UFPR in Curitiba, Brazil.
PATIENTS CHARACTHERISTICS: male: 78; female: 44; me-
dian age 17.5 years (range: 1–55). Cell source was bone marrow in
91 patients, cord blood in 29 patients and pheripheral blood in 2 pa-
tients. Conditioning regimen was nomyeloablative in 8 patients and
conventional in 114 patients. 24 patients received ATG or ALG as
part of their conditioning regimen. 39 patients had advanced disease
at the time of transplant (CML advanced phase, AML or ALL in re-
lapse or refractory). Results: Acute graft versus host disease grade
II-IV was observed in 49 patients (40%). Extensive chronic
GVHD was observed in 26 patients (21%). Acute GVHD was the
primary cause of death in 4% and chronic GVHD in 9%, infection
in 22% and relapse in 19% of the patients. Acute or chronic GVHD
was not statistically different amog alive and dead patients. Among
91 patients who received marrow or pb, acute graft-versus-host dis-
ease grade II-IV was seen in 41 patients (45%). 54 patients survived
more than 100 days and were then evaluable for chronic graft-ver-
sus-host-disease. 24 (44%) of them developed extensive chronic
GVHD. A-GVHD and C-GVHD were the primary cause of death
in 5 (8%) and 11 (18%) patients respectively. Infection (37%) and
relapse (27%)were themost frequent causes of death. Among 83 pa-
tients who received unrelated cord blood, grade II-IV acute GVHD
was seen in 29% of the patients. Chronic GVHD was observed in
16% of the 44 patients who survived more than 100 days. Acute
GVHDwere considered as primary cause of death in 7% of the pa-
tients. Infection (20%) and relapse (11%) were the main causes of
death. There was significantly more patients alive with c-GVHD.
Conclusion: The presence of chronic graft-versus-host-disease
had a protective effect at the survival of this group of patients, prob-
ably due to graft-versus-malignancy effect.388
PRIMARY TREATMENT AND PROGNOSIS OF ACUTE GRAFT-VERSUS-
HOST DISEASE (GVHD): A SINGLE-CENTER ANALYSIS OF 458 PATIENTS
Fukuda, T., Yokoyama, H., Takahashi, T., Iisaka, Y., Ohara-Waki, F.,
Kim, S.-W., Mori, S.-I., Tanosaki, R., Tobinai, K., Takaue, Y. National
Cancer Center Hospital, Tokyo, Japan.
Purpose and Methods: To clarify the optimal primary treat-
ment for acute GVHD (aGVHD) and to identify prognostic factors
that can predict outcome after aGVHD, we retrospectively re-
viewed the data of 458 patients (median age, 47 years: range, 1–
68) with hematological malignancies who underwent allogeneic
HCT between 2000 and 2006. Patients were conditioned with a re-
duced-intensity (n 5 249) or myeloablative regimen (n 5 209). Pa-
tients received BM (n5 168), G-CSF-mobilized PBSC (n5 256) or
CB (n5 34) from either an HLA-matched relative (n5 214), a mis-
matched relative (n 5 56) or an unrelated volunteer (n 5 188).
GVHD prophylaxis consisted of cyclosporine (n 5 397) or tacroli-
mus (n5 61), with or without methotrexate. The median follow-up
of surviving patients was 1379 days. Results: Grade I-IV aGVHD
occurred in 242 patients, and the timing was before disease progres-
sion or relapse in 236 patients (grade I, n 5 33; grade II, n 5 126;
grade III, n 5 57; grade IV, n 5 20). The incidence of nonrelapse
mortality (NRM) in these 236 patients with aGVHD was 32%
(grade I, 3%; grade II, 26%; grade III/IV, 53%). While 65 patients
(28%) were followed without systemic corticosteroids (grade I, n5
28; grade II, n5 37), the remaining 171 patients (72%) received sys-
temic corticosteroids as a primary treatment for aGVHD (mPSL
equivalents $2 mg/kg/day, n 5 35; 1 mg/kg/day, n 5 103; 0.2–
0.5 mg/kg/day, n 5 33). Subsequently, 62 patients were treated
with an increased dose of corticosteroids, and 25 required additional
treatment. The 2-year NRM in 70 patients with grade II GVHD
with skin involvement alone and 19 patients with upper-GI
GVHD with or without skin involvement were 20% and 19%, re-
spectively, although 36% and 79% of the patients were treated
with#0.5 mg/kg/day of mPSL. While the 2-year NRM in 112 pa-
tients who had liver or lower-GI involvement was 50%, that in 124
patients who did not was 15% (p\0.0001). In a multivariate anal-
ysis, liver or lower-GI involvement, GVHDonset within 14 days af-
ter HCT, older patient age, cyclosporine prophylaxis, and
transplant from a donor other than an HLA-matched relative
were associated with an increased risk for NRM after the develop-
ment of aGVHD. Conclusions: The initial dose of systemic corti-
costeroids can be reduced safely when GVHD manifestation
involvesmainly the skin and upperGI. Although prospective studies
are needed to confirm these findings, our study suggests that
GVHD treatment can be tailored depending on ethnicity and trans-
plantation procedures.389
EOSINOPHILIC PULMONARY SYNDROME AS A MANIFESTATION OF PUL-
MONARY GRAFT-VERSUS-HOST-DISEASE FOLLOWING HEMATOPOIETIC
STEM CELL TRANSPLANTATION IN THREE PATIENTS
Akhtari, M.1, Lanston, A.1, Waller, E.1, Gal, A.2. 1Winship Cancer In-
stitute, Emory University School of Medicine, Atlanta, GA; 2Emory Uni-
versity School of Medicine, Atlanta, GA.
Eosinophilic pulmonary syndrome has been an uncommon prob-
lem in stem cell transplant recipients that can mimic an infectious
process. We report the occurrence of three cases of eosinophilic
pulmonary syndrome as a manifestation of pulmonary graft-ver-
sus-host-disease (GVHD) in the setting of allogeneic hematopoietic
stem cell transplantation (HSCT), after day 100 post-transplant, for
hematological disorders. All three patients had skinGVHDcompli-
cating their post-transplant course. All three patients had peripheral
blood eosinophilia with their lung biopsies showing pronounced in-
filtrates of eosinophils involving bronchioles. Following the admin-
istration of high-dose systemic steroid therapy, all patients
responded rapidly with improvement of their pulmonary symptoms
and the resolution of peripheral blood eosinophilia. Clinicians
should be aware that eosinophilic pulmonary syndrome can occur
following HSCT and it can be associated with GVHD.
